Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) has shared an update.
JW (Cayman) Therapeutics has extended the term of its vector supply agreement with substantial shareholder Juno through 31 December 2028, ensuring continued access to critical vectors used in the commercialization and further clinical development of its CAR-T therapy Carteyva®. The transaction is classified as a continuing connected transaction under Hong Kong Listing Rules, subject only to reporting and announcement requirements since the applicable percentage ratios for the extended period from 2026 to 2028 remain below 5%, meaning it is exempt from circular and independent shareholder approval, and historical payments under the agreement have stayed within previously approved annual caps.
The most recent analyst rating on (HK:2126) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a Hong Kong-listed biopharmaceutical company focused on cell therapies, including the commercialization and clinical development of its CAR-T product Carteyva® for cancer treatment. The company sources key manufacturing inputs such as viral vectors from strategic partners, including substantial shareholder Juno, to support its ongoing commercial and clinical operations in the oncology space.
Average Trading Volume: 1,840,792
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.13B
For an in-depth examination of 2126 stock, go to TipRanks’ Overview page.